Sequence information
Variant position: 569 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1333 The length of the canonical sequence.
Location on the sequence:
TLERMLDVTMLQEEKEEQMR
L PSADVYRFAEPDSEENIIFE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human TLERMLDVTMLQEEKEEQMRL PSADVYRFAEPDSEENIIFE
Mouse TLERMLDVTVLQEEKEEQMRL PSAEVYRFAEPDSEENILFE
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 1333
Son of sevenless homolog 1
Alternative sequence
372 – 1333
Missing. In isoform 2.
Literature citations
Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations.
Denayer E.; Devriendt K.; de Ravel T.; Van Buggenhout G.; Smeets E.; Francois I.; Sznajer Y.; Craen M.; Leventopoulos G.; Mutesa L.; Vandecasseye W.; Massa G.; Kayserili H.; Sciot R.; Fryns J.P.; Legius E.;
Genes Chromosomes Cancer 49:242-252(2010)
Cited for: VARIANTS NS4 ARG-102; GLU-170; LYS-266; THR-269; ALA-378; LYS-433 AND GLY-552; VARIANTS VAL-569 AND LEU-655;
SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations.
Lepri F.; De Luca A.; Stella L.; Rossi C.; Baldassarre G.; Pantaleoni F.; Cordeddu V.; Williams B.J.; Dentici M.L.; Caputo V.; Venanzi S.; Bonaguro M.; Kavamura I.; Faienza M.F.; Pilotta A.; Stanzial F.; Faravelli F.; Gabrielli O.; Marino B.; Neri G.; Silengo M.C.; Ferrero G.B.; Torrrente I.; Selicorni A.; Mazzanti L.; Digilio M.C.; Zampino G.; Dallapiccola B.; Gelb B.D.; Tartaglia M.;
Hum. Mutat. 32:760-772(2011)
Cited for: VARIANTS NS4 LYS-108; ARG-112; GLU-170; THR-252; LYS-266; THR-269; ARG-269; VAL-422; LYS-424; 427-LYS--ASP-430 DELINS ASN; ARG-432; 432-TRP-GLU-433 DEL; LYS-433; ARG-434; LYS-434; THR-437; TYR-441; ARG-477; ARG-478; ARG-482; ARG-490; GLN-497; ARG-548; LYS-549; GLY-552; LYS-552; MET-552; THR-552; SER-552; 554-LEU--MET-558 DELINS LYS; PHE-733; LYS-846 AND ARG-894; VARIANTS ALA-37; LEU-478; VAL-569; LEU-655; THR-708; THR-784; SER-1011; LYS-1131; ILE-1140; ALA-1257 AND ARG-1320;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.